Alphagan P

Open-angle glaucoma, Rosacea, Glaucoma + 4 more
Treatment
6 FDA approvals
20 Active Studies for Alphagan P

What is Alphagan P

BrimonidineThe Generic name of this drug
Treatment SummaryBrimonidine is a drug used to treat glaucoma and reduce intraocular pressure. It is a type of alpha-adrenergic agonist, a class of drugs that work by narrowing the blood vessels in the eye. It is the only alpha-adrenergic agonist specifically approved for chronic glaucoma treatment. It is also approved for treating persistent facial redness caused by rosacea. Brimonidine is a safe alternative to beta-blockers for those with or at risk of cardiopulmonary diseases. It is available as a topical solution and was FDA approved in 1996.
Alphagan Pis the brand name
Alphagan P Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Alphagan P
Brimonidine
2001
43

Approved as Treatment by the FDA

Brimonidine, commonly known as Alphagan P, is approved by the FDA for 6 uses including Increased Intra Ocular Pressure (IOP) and Open Angle Glaucoma .
Increased Intra Ocular Pressure (IOP)
Helps manage Increased Intra Ocular Pressure (IOP)
Open Angle Glaucoma
Helps manage Open Angle Glaucoma (OAG)
Glaucoma
Helps manage Increased Intra Ocular Pressure (IOP)
Open Angle Glaucoma (OAG)
Helps manage Open Angle Glaucoma (OAG)
Ocular Hypertension
Helps manage Ocular Hypertension
Ocular Hypertension
Helps manage Ocular Hypertension

Effectiveness

How Alphagan P Affects PatientsBrimonidine is an alpha-2 adrenergic receptor agonist. This means it targets certain receptors in the body, which helps it reduce the risk of systemic side effects like low blood pressure, low heart rate, and sleepiness. It is also thought to have less negative effects on the eyes than other drugs, though it can still cause eye issues like redness and constriction. Brimonidine has a peak effect two hours after it is taken and can effectively lower eye pressure for up to a year. In addition, it has anti-inflammatory properties and can help reduce redness in those with rosacea. When taken systemically
How Alphagan P works in the bodyBrimonidine works to lower the intraocular pressure (IOP) of the eye. It does this by activating alpha-2 adrenoceptors, which causes a decrease in norpinephrine release, inhibition of adenylyl cyclase, and a decrease in cyclic AMP levels. This leads to a reduction in aqueous humor production, which helps to reduce IOP. This drug is used to treat glaucoma and ocular hypertension, as well as facial erythema of rosacea. It works on the skin by causing vasoconstriction of small arteries and veins, reducing redness and

When to interrupt dosage

The recommended amount of Alphagan P is reliant upon the diagnosed condition, including Open Angle Glaucoma, facial erythema and Ocular Hypertension. The dose fluctuates, in keeping with the technique of delivery featured in the table beneath.
Condition
Dosage
Administration
Ocular Hypertension
, 1.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 2.0 mg/mg, 0.2 %, 0.15 %, 0.33 %, 0.003 mg/mg, 0.005 mg/mg, 0.25 mg/mL, 0.0025 mg/mg, 0.025 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops, Solution, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Gel, Topical, Gel - Topical, Cutaneous, Gel - Cutaneous, Suspension, Suspension - Ophthalmic
Glaucoma
, 1.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 2.0 mg/mg, 0.2 %, 0.15 %, 0.33 %, 0.003 mg/mg, 0.005 mg/mg, 0.25 mg/mL, 0.0025 mg/mg, 0.025 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops, Solution, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Gel, Topical, Gel - Topical, Cutaneous, Gel - Cutaneous, Suspension, Suspension - Ophthalmic
Open Angle Glaucoma
, 1.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 2.0 mg/mg, 0.2 %, 0.15 %, 0.33 %, 0.003 mg/mg, 0.005 mg/mg, 0.25 mg/mL, 0.0025 mg/mg, 0.025 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops, Solution, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Gel, Topical, Gel - Topical, Cutaneous, Gel - Cutaneous, Suspension, Suspension - Ophthalmic
Open-angle glaucoma
, 1.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 2.0 mg/mg, 0.2 %, 0.15 %, 0.33 %, 0.003 mg/mg, 0.005 mg/mg, 0.25 mg/mL, 0.0025 mg/mg, 0.025 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops, Solution, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Gel, Topical, Gel - Topical, Cutaneous, Gel - Cutaneous, Suspension, Suspension - Ophthalmic
Rosacea
, 1.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 2.0 mg/mg, 0.2 %, 0.15 %, 0.33 %, 0.003 mg/mg, 0.005 mg/mg, 0.25 mg/mL, 0.0025 mg/mg, 0.025 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops, Solution, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Gel, Topical, Gel - Topical, Cutaneous, Gel - Cutaneous, Suspension, Suspension - Ophthalmic
Glaucoma
, 1.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 2.0 mg/mg, 0.2 %, 0.15 %, 0.33 %, 0.003 mg/mg, 0.005 mg/mg, 0.25 mg/mL, 0.0025 mg/mg, 0.025 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops, Solution, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Gel, Topical, Gel - Topical, Cutaneous, Gel - Cutaneous, Suspension, Suspension - Ophthalmic
facial erythema
, 1.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL, 2.0 mg/mg, 0.2 %, 0.15 %, 0.33 %, 0.003 mg/mg, 0.005 mg/mg, 0.25 mg/mL, 0.0025 mg/mg, 0.025 %
, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops, Solution, Solution - Ophthalmic, Liquid, Liquid - Ophthalmic, Gel, Topical, Gel - Topical, Cutaneous, Gel - Cutaneous, Suspension, Suspension - Ophthalmic

Warnings

Alphagan P Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Brimonidine may interact with Pulse Frequency
There are 20 known major drug interactions with Alphagan P.
Common Alphagan P Drug Interactions
Drug Name
Risk Level
Description
Oliceridine
Major
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Brimonidine is combined with Oliceridine.
Acebutolol
Minor
Brimonidine may increase the antihypertensive activities of Acebutolol.
Aliskiren
Minor
Brimonidine may increase the antihypertensive activities of Aliskiren.
Alprenolol
Minor
Brimonidine may increase the antihypertensive activities of Alprenolol.
Ambrisentan
Minor
Brimonidine may increase the antihypertensive activities of Ambrisentan.
Alphagan P Toxicity & Overdose RiskThe lethal dose (LD50) of brimonidine is 50 mg/kg in mice and 100 mg/kg in rats. People who overdose on this drug may experience low blood pressure, weakness, vomiting, drowsiness, slow heartbeat, abnormal heart rhythms, narrowed pupils, pauses in breathing, low body temperature, and seizures. Treatment for an overdose includes supportive care. In pregnant and breastfeeding women, the benefits and risks should be carefully weighed before taking the drug. Brimonidine is considered safe to use in elderly patients, but it is not recommended for infants under two years old or children under 18 due to reports of serious side effects

Alphagan P Novel Uses: Which Conditions Have a Clinical Trial Featuring Alphagan P?

Currently, 114 active clinical trials are assessing Alphagan P's potential to address Open Angle Glaucoma, inadequately managed Intraocular Pressure and Open Angle Glaucoma.
Condition
Clinical Trials
Trial Phases
Open-angle glaucoma
45 Actively Recruiting
Not Applicable, Phase 2, Phase 3, Phase 4, Early Phase 1, Phase 1
Glaucoma
0 Actively Recruiting
facial erythema
0 Actively Recruiting
Rosacea
0 Actively Recruiting
Glaucoma
0 Actively Recruiting
Ocular Hypertension
10 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable, Phase 4
Open Angle Glaucoma
10 Actively Recruiting
Phase 3, Not Applicable, Phase 4

Patient Q&A Section about alphagan p

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Alphagan P used for?

"This medication is used to treat open-angle glaucoma, which is when there is too much fluid pressure in the eye. If left untreated, open-angle glaucoma can lead to vision loss, nerve damage, or blindness. This medication works by reducing the amount of fluid pressure in the eye, which lowers the risk of vision loss or damage to the eye."

Answered by AI

What is the difference between ALPHAGAN and Alphagan P?

"Alphagan P 1.5 contains a preservative called 'purite,' while Alphagan contains benzalkonium chloride. Your doctor may have prescribed Alphagan P 1.5 for another reason."

Answered by AI

What class of drug is Alphagan P?

"Alphagan-P is a drug used to treat symptoms like increased pressure in the eye and redness. It can be used by itself or with other medications, and belongs to a class of drugs called antiglaucoma alpha agonists."

Answered by AI

How long does it take Alphagan P to work?

"Brimonidine (Alphagan P) typically lowers eye pressure within 2 to 3 hours, but may not provide consistent results for a few weeks. Your eye pressure is best controlled if you use this medication 3 times a day every day."

Answered by AI

Clinical Trials for Alphagan P

Have you considered Alphagan P clinical trials? We made a collection of clinical trials featuring Alphagan P, we think they might fit your search criteria.Go to Trials
Have you considered Alphagan P clinical trials? We made a collection of clinical trials featuring Alphagan P, we think they might fit your search criteria.Go to Trials
Image of Twin Cities Eye Consultants in Coon Rapids, United States.

Laser Treatment for Glaucoma

18+
All Sexes
Coon Rapids, MN
The GLASS Study is designed to help researchers learn whether repeating a non-invasive laser treatment called DSLT (Direct Selective Laser Trabeculoplasty) can better control eye pressure in patients with early-stage glaucoma or ocular hypertension. All participants will receive the laser treatment in both eyes. After three months, one eye will be randomly selected to receive a second treatment, while the other eye will serve as a comparison. The goal is to see whether two treatments work better than one at keeping eye pressure low without using daily eye drops. This study will help doctors decide the best way to use this laser treatment to manage glaucoma and delay the need for medication. Participants will be followed for one year to monitor safety, eye pressure, and the need for any additional treatments.
Recruiting
Has No Placebo
Twin Cities Eye ConsultantsGeorge R Wandling, MDAlcon Research
Image of University of California, San Francisco in San Francisco, United States.

Community Support + Text Reminders for Eye Disease

18+
All Sexes
San Francisco, CA
The goal of this randomized, parallel-group, controlled trial is to compare methods of improving linkage-to-care for participants in the Village Integrated Eye Worker II (VIEW II) trial who are referred to the eye hospital following eye disease screening. Participants who are referred to the hospital at an eye screening visit will be randomized to three different linkage-to-care interventions: (1) text message reminders, (2) reminders from health workers, or (3) no intervention. The primary outcome of the trial will be whether or not the participant presented to the eye hospital for a referral visit by 21 days following screening.
Waitlist Available
Has No Placebo
University of California, San FranciscoJeremy Keenan, MD, MPH
Have you considered Alphagan P clinical trials? We made a collection of clinical trials featuring Alphagan P, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security